Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $236.7352W HIGH $396.23
Volume
183.09 K
Value Traded
77.95 M
Short % Float
6.15%
Days to Cover
4.8
-0.07%Week
+4.67%1 Month
+11.19%3 Month
+44.33%6 Month
-52.22%5 Year
+11,159.22%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.95 B
EPS (TTM)
8.32
P/E Ratio
44.75
Ent. Value
9.54 B
Total Shares
26.74 M
Float Shares
17.85 M
Insiders
33.25%
Institutions
72.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BIO Catalyst Timeline
Dated clinical, regulatory and corporate events for Bio-Rad Laboratories, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bio-Rad Laboratories, Inc.
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How BIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Bio-Rad Laboratories, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BIO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DiVincenzo Jonathan P.Officer (President & COO) | Option | 1,869 3,832 held | $0.00 | 10/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 0.4 % | 4.11 M | 13.99 K |
BIO Institutional Ownership Trends
BIO Short Interest
Shares sold short, counted twice a month.
6.15%
Short % of Float
of tradable shares sold short
1.1M
Shares Sold Short
-7.2% vs prior count
4.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
226.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BIO ranks across every disease it competes in
Competitive Position is a premium feature
See how BIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBIO News
BIO▼ -3.2%today
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
Bio-Rad Laboratories announced that CFO Roop K. Lakkaraju will participate in a fireside chat at the UBS Global Healthcare Conference on November 10, 2026. The event is scheduled for 8:00 AM Eastern Time. A live webcast and replay will be available on the company's Investor Relations website.
Read more →BIOBio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
Bio-Rad Laboratories, Inc. will announce its third-quarter financial results for 2026 on November 4, 2026. The announcement will follow the market's close, with a conference call scheduled for 2:00 PM PT. Interested parties can participate via phone or a live webcast, which will also be available for replay for up to a year.
Read more →BIOBio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
Bio-Rad Laboratories, Inc. announced that its CFO, Roop K. Lakkaraju, will participate in a fireside chat at the Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum. The event is scheduled for September 24, 2026, at 8:50 AM Eastern Time. A live webcast and replay will be available for investors.
Read more →BIOBio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
Bio-Rad Laboratories, Inc. announced that its CFO, Roop K. Lakkaraju, will participate in a fireside chat at Wells Fargo's 21st Annual Healthcare Conference on September 9, 2026. The event will provide a platform for discussing the company's strategies and insights. A live webcast and replay will be accessible for investors.
Read more →BIOBio-Rad Reports Second-Quarter 2026 Financial Results
Bio-Rad Laboratories, Inc. reported its financial results for Q2 2026, revealing flat revenue year-over-year. The Clinical Diagnostics segment showed growth, but this was offset by challenges in the Life Science segment. CEO Norman Schwartz highlighted the company's ongoing leadership in life science research despite these headwinds.
Read more →BIOBio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
Bio-Rad Laboratories, Inc. will announce its second-quarter 2026 financial results on August 4, 2026. The report will be released after market close, followed by a conference call at 2:00 PM PT. This engagement allows stakeholders to discuss the results directly with management.
Read more →BIOBio-Rad to Participate in Upcoming Investor Conferences
Bio-Rad is set to participate in upcoming investor conferences, indicating its ongoing engagement with investors. The participation may provide insights into the company's strategies and future directions. However, specific details about the conferences or presentations were not disclosed in the article.
Read more →BIOBio-Rad Reports First-Quarter 2026 Financial Results
Bio-Rad Laboratories, Inc. reported its first-quarter 2026 financial results, showing a 1.1% increase in net sales year-over-year, despite facing external challenges. The company experienced a significant net loss of $527.1 million, primarily due to changes in the fair market value of its investments. Additionally, Bio-Rad updated its full-year financial outlook, anticipating a potential revenue decline.
Read more →BIOBio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
Bio-Rad Laboratories is scheduled to release its financial results for the first quarter of 2026 on April 30, 2026. This announcement is part of the company's regular financial reporting cycle, providing stakeholders with insights into its performance. The report will likely cover various financial metrics and operational highlights for the quarter.
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
Bio-Rad Laboratories, Inc. announced its financial results for Q4 and the full year of 2025, reporting modest revenue growth but lower gross and operating margins than anticipated. The company successfully integrated its recent acquisition, Stilla Technologies, into its product offerings, contributing to growth in its digital PCR segment. However, challenges in the Life Science segment and geopolitical uncertainties affected overall market conditions. Looking ahead, Bio-Rad anticipates moderate revenue growth for 2026.
Read more →BIOBio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
Bio-Rad Laboratories, Inc. will announce its financial results for Q4 and the full year 2025 on February 12, 2026. A conference call is scheduled for 2:00 PM PT to discuss these results. The company continues to operate as a leader in life science and clinical diagnostics, serving various sectors.
Read more →BIOBio-Rad Reports Third -Quarter 2025 Financial Results
Bio-Rad Laboratories, Inc. announced its financial results for the third quarter ending September 30, 2025. The company reported a slight increase in net sales but faced significant GAAP net losses primarily due to investment evaluations. Non-GAAP results showed growth in income, but overall demand for products has been affected by ongoing challenges in the biotech sector. Full-year financial outlook remains unchanged, forecasting modest growth.
Read more →BIOBio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
Alice N. Schwartz, co-founder and Director Emeritus of Bio-Rad Laboratories, passed away at 99 on September 25, 2025. Schwartz, who co-founded the company in 1952 with her husband, played a significant role in developing Bio-Rad's first diagnostic test kit. She remained active within the company until 2022, inspiring generations of scientists and contributing greatly to Bio-Rad's legacy in life science research and diagnostics.
Read more →BIOBio-Rad Reports Second -Quarter 2025 Financial Results
Bio-Rad Laboratories, Inc. reported its second-quarter 2025 financial results, showcasing a revenue increase of 2.1% year-over-year. The company recorded a significant net income of $317.8 million, recovering from a net loss in the same period last year. Key contributors to this growth included higher sales in the Life Science segment and the acquisition of Stilla Technologies, enhancing their product portfolio. However, the Clinical Diagnostics segment faced challenges, particularly due to reduced reimbursements for diabetes testing in China.
Read more →BIOBio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
Bio-Rad Laboratories has appointed Rajat Mehta as the new Executive Vice President of Global Commercial Operations, effective August 4, 2025. Mehta succeeds Mike Crowley, who is retiring after 26 years with the company. With a strong background in the biopharmaceutical and diagnostics sectors, Mehta previously held senior leadership roles at Labcorp and Thermo Fisher Scientific. Bio-Rad's leadership anticipates that Mehta's expertise will contribute significantly to the company's ongoing strategy and growth in the commercial sector.
Read more →BIOBio-Rad Reports First -Quarter 2025 Financial Results
Bio-Rad Laboratories, Inc. has reported its financial results for the first quarter of 2025, highlighting a decrease in total revenue of 4.2% compared to the same period in 2024. The company's net income has sharply fallen from $383.9 million to $64.0 million, attributed to lower sales in its Life Science segment and challenges in the academic research market. Bio-Rad has adjusted its full-year 2025 outlook, expecting revenue to range from a decline of 1.0% to a growth of 1.5%. Despite these challenges, the company remains committed to its growth initiatives and improving operational margins.
Read more →BIOBio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
Bio-Rad Laboratories, Inc. reported its fourth-quarter and full-year financial results for 2024, indicating a decrease in sales driven primarily by challenges in the Life Science segment. While the Clinical Diagnostics business showed slight growth, the overall financial performance reflected a net loss largely attributed to investment value changes. The company plans to enhance its product portfolio through the anticipated acquisition of Stilla Technologies and aims for continued margin expansion amid ongoing challenges.
Read more →BIOBio-Rad Reports Third-Quarter 2024 Financial Results
Bio-Rad Laboratories, Inc. reported its third-quarter financial results for 2024, showing net sales of $649.7 million, a 2.8% increase compared to the prior year, primarily driven by the Clinical Diagnostics segment. However, the Life Science segment experienced a slight decline of 1.0%. The company's gross margin improved, reaching 54.8%, while overall income from operations saw a decrease from the previous year. Despite challenges in the biotech market, Bio-Rad remains optimistic about future growth with new leadership in place.
Read more →BIOBio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
Bio-Rad Laboratories, Inc. has appointed Jon DiVincenzo as President and Chief Operating Officer, effective September 9, 2024. He will replace Andy Last, who is retiring. DiVincenzo previously held leadership roles at Labcorp Holdings and PerkinElmer, bringing over thirty years of experience in the life sciences and clinical diagnostics sectors. His appointment is expected to support Bio-Rad's ongoing growth and transformational goals.
Read more →BIOBio-Rad Reports Second-Quarter 2024 Financial Results
Bio-Rad Laboratories reported its financial results for the second quarter of 2024, revealing a 6.3% decline in total net sales compared to the previous year, driven largely by a 16.5% decrease in the Life Science segment. While the Clinical Diagnostics segment saw a slight increase in sales, the overall results were impacted by a substantial net loss driven by the change in market value of investments. The company has adjusted its full-year revenue outlook downward, anticipating a decline instead of growth. Despite challenges, management remains optimistic about margins improving due to ongoing supply chain initiatives and cost control measures.
Read more →About Bio-Rad Laboratories, Inc.
Headquarters1000 ALFRED NOBEL DRIVE, HERCULES, CA, 94547
BIOPHARMAWATCH ELITE PLUS
Trade the next BIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime